Tiziana Life Sciences Ltd (TLSA) - Form 20-F Summary
Business Context and Reporting Period
Company: Tiziana Life Sciences Ltd (Bermuda-incorporated, NASDAQ: TLSA)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Model: Clinical-stage biotechnology company focused on developing immunotherapies for neurodegenerative and neuroinflammatory diseases. The company operates a lean, virtual R&D model.
Lead Asset: Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody, currently in Phase 2a trials for Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA).
Accounting Basis: International Financial Reporting Standards (IFRS).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 ($000s) | 2024 ($000s) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(18,431) | $(11,863) |
| Operating Expenses | $(21,132) | $(15,794) |
| Research & Development | $(10,279) | $(5,229) |
| General & Administrative | $(10,853) | $(10,565) |
| Cash and Cash Equivalents | $4,010 | $3,724 |
| Working Capital | $(2,657) | $160 |
| Total Assets | $11,495 | $11,284 |
| Total Liabilities | $11,443 | $7,348 |
| Shareholders' Equity | $52 | $3,936 |
| Outstanding Shares | 120,507,401 | 111,462,617 |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $6.6 million (55%) to $18.4 million, driven primarily by a $5.1 million increase in R&D expenses due to the initiation of Phase 2 trials for Foralumab in SPMS, MSA, and Alzheimer's, and the commencement of an Open Label Extension study.
- Investment Gains: The company recognized a net gain of $2.7 million in "Other Income," reversing a loss of $0.95 million in 2024. This was largely due to a $3.0 million gain on the sale of shares in related party Okyo Pharma Ltd. and fair value increases in investments in Okyo and Accustem Sciences.
- Liquidity Deterioration: Working capital turned negative to $(2.7) million from a positive $0.16 million in 2024, reflecting increased current liabilities (accounts payable and accrued expenses) outpacing current assets.
- Share Capital: Issued approximately 9 million new shares during 2025 via At-The-Market (ATM) offerings and exercises of options/warrants, raising approximately $10.1 million in net proceeds.
Guidance, Outlook, and Risks
Going Concern Uncertainty: Independent auditors (PKF Littlejohn LLP) have issued a "Going Concern" emphasis of matter. The company's cash flow projections indicate it will not be able to meet liabilities as they fall due within the next 12 months without additional financing. Management is pursuing equity raises and cost reductions to address this.
Recent Financing (Subsequent Event): In January 2026, the company completed a registered direct offering raising approximately $8.6 million (net) by selling 7.04 million shares at $1.25/share. Purchasers included the CEO and an entity associated with the Executive Chairman. Warrants were issued with an exercise price of $1.50.
Clinical Outlook:
- na-SPMS: Phase 2a trial enrollment is underway; top-line data expected in H2 2026. FDA granted Fast Track designation in July 2024.
- Alzheimer's: Phase 2 trial enrollment began in December 2025.
- ALS & MSA: Phase 2a trials initiated or accepted into consortium programs (ALS MyMatch).
Key Risks:
- Capital Requirements: Substantial additional funding is required to complete clinical trials; failure to raise capital could force curtailment of operations.
- Clinical Failure: High risk of failure in clinical trials; negative results in one indication (e.g., SPMS) could cast doubt on the mechanism of action for others (e.g., AD, ALS).
- Intellectual Property: Reliance on in-licensed patents from Novimmune and Brigham and Women's Hospital; obligations include milestone payments and royalties.
- Regulatory: Uncertainty regarding FDA/EMA approval timelines and potential for clinical holds.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.6 million raised in January 2026 combined with existing cash ($4.0 million) to fund operations through the expected H2 2026 data readouts.
- Related Party Transactions: Review the terms of the January 2026 offering where senior management and affiliates were primary purchasers, and the valuation of investments in related parties (Okyo, Accustem) which contributed significantly to 2025 income.
- Clinical Trial Progress: Monitor patient enrollment rates in the Phase 2a trials for na-SPMS, MSA, and Alzheimer's to ensure timelines for 2026 data readouts are realistic.
- License Obligations: Assess the impact of upcoming milestone payments to Bristol-Myers Squibb (BMS) and Brigham and Women's Hospital upon trial progression.
- Going Concern Status: Evaluate the company's ability to secure further funding if the January 2026 proceeds are insufficient to reach profitability or a major partnership milestone.